Long-Lived Engineering of Glycans to Direct Stem Cell Fate by Pulsipher, Abigail et al.
Supporting Information
 Wiley-VCH 2014
69451 Weinheim, Germany
Long-Lived Engineering of Glycans to Direct Stem Cell Fate**
Abigail Pulsipher, Matthew E. Griffin, Shannon E. Stone, and Linda C. Hsieh-Wilson*
anie_201409258_sm_miscellaneous_information.pdf
! S1 
Table of Contents 
1. Supporting Schemes S2 
2. Supporting Figures S4 
3. Supporting Table S9 
4. Materials and Methods S10 
4.1. Reagents and materials S10 
4.2. General synthetic procedures S11 
4.3. Synthesis of chloroalkane linker (CL) 1 S12 
4.4. Synthesis of compounds for method validation S13 
4.5. Synthesis of compounds for biological assays S15 
4.6. General biological procedures S16 
4.7. 1H NMR spectra of representative compounds S22 
5. References S25 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
! S2 
 
 
 
 
 
 
 
 
Scheme S1. Synthesis of chloroalkane linker (CL) 1 and chloroalkane-conjugated fluorescein (F-
CL). Conditions: a) Boc2O (2 eq), MeOH, 0 °C, 2 h, 91%; b) 60% NaH (1.5 eq), DMF, 0 °C, 1 h; 
c) 1-chloro-6-iodohexane (1.2 eq), 24 h, 37% over two steps; d) TFA (6 eq), DCM, 4 h; e) 4 (1 
eq), DCM, 24 h, 67% over two steps; f) 5-(((2-(carbohydrazino)methyl)thio)acetyl)-
aminofluorescein (F) (0.5 eq), MeOH, 16 h, 75%. MeOH = methanol, NaH = sodium hydride, 
DMF = N,N-dimethylformamide, TFA = trifluoroacetic acid, DCM = dichloromethane, EDC = 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. 
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Scheme S2. Synthesis of biotinylated heparan sulfate with and without the chloroalkane linker 
(B-HS and B-HS-CL). Conditions: a) BrCN (excess), 0.2 M NaOH, pH 11, 10 min; b) 
BiotinPEG4NH2 (excess), 0.2 M sodium borate, pH 8, 12 h; c) 1 (excess), NaBH3CN (excess), 
MeOH, ddH2O, 16 h. Step (c) was also used to synthesize all HS-CL derivatives listed in Figure 
1B. PEG = polyethylene glycol, ddH2O = deionized water. 
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Figure S1. Specificity controls for the HTP anchoring strategy. A) CHO cells stably expressing 
HTP do not incorporate fluorescein lacking the chloroalkane linker.  Cells were incubated with 
5-(((2-(carbohydrazino)methyl)thio)acetyl)-aminofluorescein (F) for 1 h at 37 °C. Cultures were 
then stained with DAPI (blue) and imaged at the indicated time points. No appreciable 
fluorescein (green) signal was observed. B) CHO cells lacking HTP do not incorporate B-HS-CL 
into their membranes.  Cells were transfected with an empty pDisplay vector (pD; no HTP insert), 
incubated with B-HS-CL for 6 h at 37 °C, and stained with DAPI (blue), streptavidin-IRDye800 
(green), and an anti-HA antibody (red). No appreciable biotin signal (green) was observed. HTP 
= HaloTag protein, HA = hemagglutinin, DAPI = 4’,6-diamidino-2-phenylindole. Scale bars 
represent 20 µm. 
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Figure S2. Cell-surface presentation of HS GAGs on ESCs does not induce FGF2-mediated 
ERK1/2 phosphorylation in the absence of HTP expression. Mouse ESCs were mock transfected 
with an empty pDisplay vector (pD; no HTP insert), incubated with the indicated HS-CL 
derivatives, washed, stimulated with FGF2, and analyzed for phospho-ERK levels as described. 
No significant differences were observed between untreated cells and cells treated with the HS-
CL derivatives, suggesting that cell-surface anchoring of HS-CL onto HTPs is required for 
inducing ERK activation. Data represent the mean ± S.E.M. from three independent experiments 
(n = 3). P > 0.05 for all conditions when compared to the untreated control. 
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Figure S3. FGF8b and its receptor FGFR3c are capable of forming ternary complexes with 
heparin/highly sulfated HS. Microarrays printed with various concentrations of the HS 
derivatives (0.5 to 10 µM) were incubated with an FGFR3c-Fc fusion protein in the presence 
(blue bars) or absence (black bars) of FGF8b. Binding of FGFR3c-Fc was visualized using an 
AF647-conjugated goat anti-human Fc antibody and quantified by measuring the fluorescence 
intensity at each spot. Data represent the mean ± S.E.M. from ten replicate microarray spots and 
were normalized with respect to the maximum fluorescence intensity on the array. 
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Figure S4. Surface display of highly sulfated HS induces accelerated self-renewal exit, neural 
lineage commitment, and differentiation into mature, neuronal cells. mESCs were fixed at the 
indicated time points and stained by immunocytochemistry for A) pluripotent marker NANOG, 
B) neuroectoderm marker SOX1, or C) neuronal marker TUJ1. NANOG is shown in green, 
SOX1 and TUJ1 in red, and DAPI-stained nuclei in blue. Scale bars represent 20 µm. 
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Figure S5. ESCs treated with HS-CL develop more extensive neuronal processes compared to 
untreated cells and de-HS-CL treated cells. Cells were stained with an anti-TUJ1 antibody (red) 
and DAPI (a nuclei marker, blue) 9 and 12 days after treatment with the indicated HS derivative. 
As indicated in red, more elaborate neurite processes were observed for cells treated with HS-
CL compared to untreated cells and cells treated with de-HS-CL at both time points. Scale bars 
represent 50 µm.  
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Table S1. qRT-PCR primers used in this study. 
Gene Forward Primer Reverse Primer Amplicon (bp) 
GAPDH AAC AGA AAC TCC CAC TCT TC CCT GTT GCT GTA GCC GTA TT 111 
SDHA GCT GGA GAA GAA TCG GTT ATG A GCA TCG ACT TCT GCA TGT TTA G 97 
NANOG TTT GGA AGC CAC TAG GGA AAG CCA GAT GTT GCG TAA GTC TCA TA 115 
SOX1 ACA CAC ACA CAC ACA CTC TC CCT CAA GAT CTG GTC AGG AAT G 101 
TUJ1 CCA TTC TGG TGG ACT TGG AA GCA CCA CTC TGA CCA AAG ATA 103 
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Materials and Methods 
Reagents and materials. 
Chemicals and biochemical reagents. All chemicals and reagents were analytical grade, obtained from Sigma-
Aldrich (St. Louis, MO), and used without further purification unless specified. Heparin/HS derivatives were 
purchased from Neoparin, Inc. (Alameda, CA). Primary antibodies against HA (rabbit mAb, 3724), Myc (mouse 
mAb, 2276), p44/42 MAP kinase (ERK, mouse mAb, 4696), phospho-p44/42 MAP kinase (phospho-ERK, rabbit 
mAb, 4370), NANOG (rabbit mAb, 8842), and βIII-tubulin/TUJ1 (rabbit mAb, 5568) and the IRDye800 goat anti-
rabbit IgG antibody were purchased from Cell Signaling Technology, Inc. (Beverly, MA). Secondary antibodies 
(AlexaFluor (AF) 680 goat anti-rabbit, AF680 goat anti-mouse, AF568 donkey anti-goat, AF568 goat anti-mouse, 
and AF488 goat anti-rabbit), AF488 streptavidin, and 5-(((2-(carbohydrazino)methyl)thio)acetyl)-aminofluorescein 
(F) were obtained from Life Technologies, Inc. (Carlsbad, CA). The AF647 goat anti-human Fc antibody was 
purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). Recombinant human basic FGF 
(FGF2), FGF8b, FGFR1 alpha IIIc Fc chimera (FGFR1-Fc), FGFR3c IIIc Fc chimera (FGFR3c-Fc), and polyclonal 
goat anti-SOX1 antibody (AF3369) were purchased from R&D Systems, Inc. (Minneapolis, MN). 
Cell culture materials. All cell culture-related medium and supplements (TrypLE Express, Hank’s balanced salt 
solution (HBSS), phosphate-buffer saline (PBS), Dulbecco's modified eagle's medium (DMEM), GlutaMAX, 
trypsin, fetal bovine serum (FBS), penicillin/streptomycin (P/S), N2, and B27) were received from Life 
Technologies Inc. unless otherwise specified. XfectTM mESC Transfection Reagent was obtained from Clontech 
Laboratories, Inc. (Mountain View, CA). Mitomycin C from Streptomyces caespitosus (475820) was purchased 
from EMD Millipore Corp. (Temecula, CA). Mouse embryonic stem cells (mESCs; ES-E14TG2a, CRL-1821) and a 
Chinese hamster ovary (CHO; pgsB-618, CRL-2241) cell line deficient in galactosyltransferase I were obtained 
from American Type Culture Collection (ATCC; Manassas, VA). F12 and DMEM culture medium and non-heat-
inactivated FBS used for mESC culture were also purchased from ATCC. Mouse embryonic fibroblasts (MEFs; 
GSC-6001) were purchased from AMSBIO Biotechnology, Ltd. (Irvine, CA). PerfeCTa® SYBR® Green FastMix®, 
ROXTM (95073-05K) was purchased from Quanta Biosciences (Gaithersburg, MD). 
! S11 
General synthetic procedures.  
Unless specifically stated, all reactions were conducted in flame-dried glassware under an argon (Ar) atmosphere 
using anhydrous solvents. All solvents and commercially available reagents were obtained from Sigma-Aldrich or 
Thermo Fisher Scientific, Inc. (Pittsburgh, PA) and used as received, unless specified otherwise. Thin-layer 
chromatography was performed using silica gel 60 F254 pre-coated plates (0.25 mm) (E. Merck KG, Darmstadt, 
Germany), and ICN silica gel (0.032-0.063 mm particle diameter) (Analtech Inc., Newark, DE) was employed for 
flash chromatography. Molecular masses of intermediate and final compounds were analyzed using an Agilent 1100 
LC-MS (Agilent, Santa Clara, CA), and 1H NMR data were obtained using Varian Mercury 300 (300 MHz), Varian 
Inova 500 (500 MHz), or Varian Inova 600 (600 MHz) spectrometers and are reported in parts per million (δ) 
relative to CDCl3 (7.26 ppm) or D2O (4.79 ppm). For small molecules, 1H NMR data are reported with the 
following: multiplicity (s = singlet, bs = broad singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, 
and m = multiplet), coupling constant (Hz), and integration values. For polysaccharides, 1H NMR data are reported 
in two separate sections: the disaccharide unit and substoichiometric components (i.e., N-acetyl, biotin(PEG)4, 
chloroalkane linker (CL)). Peaks for substoichiometric components within the disaccharide region were broad and 
partially obscured and therefore are not reported. Integration values are reported relative to each component and 
percent incorporation per disaccharide unit.  Incorporation of biotin(PEG)4 or CL is estimated using NMR peak 
intensities compared to the GlcN C-2 proton peak (~3.29 ppm) and is reported as the average number of molecules 
per polysaccharide, assuming polysaccharides (12-13 kDa) had an average length of 22 disaccharide units. 
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Synthesis of chloroalkane linker (CL) 1.  
The chloroalkane linker 1 was synthesized using procedures adapted from So et al.1 and Huang et al.2 The 1H NMR 
and MS values were in good agreement with previously reported values.1 
N-Boc-2-(2-hydroxyethoxy)ethylamine (2).1 A solution of di-tert-butyl dicarbonate (Boc2O) (2.18 g, 10.0 mmol, 1 
eq) in anhydrous methanol (2 mL) was added dropwise to a stirring solution of 2-(2-aminoethoxy)ethanol (1.05 g, 
9.99 mmol) in anhydrous methanol (20 mL) at 0 °C. The mixture was stirred for 30 min at 0 °C and then warmed to 
RT. After 2 h, the solution was diluted with DCM (30 mL), washed with ddH2O (3 x 25 mL) and brine (1 x 25 mL), 
dried over MgSO4, filtered, and concentrated to afford a colorless oil 2 (1.85 g, 91%). 1H NMR (500 MHz, CDCl3): 
δ 1.42 (s, 9H, CH3), 3.30 (t, J = 5.1 Hz, 2H, CH2N), 3.49-3.58 (m, 4H, CH2OCH2), and 3.68-3.75 (m, 2H, CH2OH). 
MS (ESI) calcd. for C4H11NO2+ [M + H+] 206.14, found 206.10.  
N-Boc-1-(2-(2-aminoethoxy)ethoxy-6-chlorohexane (3).1 A solution of 2 (0.34 g, 1.7 mmol) in DMF (2 mL) was 
added dropwise to a stirring solution of 60% NaH (0.095 g, 2.4 mmol, 1.4 eq) in DMF (30 mL) at 0 °C. The mixture 
was stirred for 1 h at 0 °C, after which 1-chloro-6-iodohexane (0.30 mL, 2.0 mmol, 1.2 eq) was added. Stirring was 
continued for 24 h at RT, and then the reaction was quenched with 1 M HCl and extracted with DCM, ddH2O (6 x 
25 mL) and brine (1 x 25 mL), dried over MgSO4, filtered, and concentrated to afford a yellow oil. Purification by 
silica gel flash chromatography using 3:1 Hex/EtOAc gave 3 as a colorless oil (0.20 g, 37%). 1H NMR (500 MHz, 
CDCl3): δ 1.33-1.40 (m, 2H, CH2), 1.43 (s, 9H, CH3), 1.44-1.48 (m, 2H, CH2), 1.55-1.64 (m, 2H, CH2), 1.73-1.80 
(m, 2H, CH2), 3.30 (t, J = 5.2 Hz, 2H, CH2N), 3.45 (t, J = 6.7 Hz, 2H, CH2Cl), 3.49-3.57 (m, 6H, CH2O), and 3.57-
3.61 (m, 2H, CH2O). MS (ESI) calcd. for C14H29ClNO5+ [M + H+] 324.20, found 324.21.  
2,5-Dioxopyrrolidin-1-yl 4-oxopentanoate (4).2 N-Hydroxysuccinimide (NHS; 0.55 g, 4.8 mmol, 1.1 eq) and 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) hydrochloride (0.91 g, 4.8 mmol, 1.1 eq) were added to a 
stirring solution of levulinic acid (0.50 g, 4.3 mmol) in anhydrous DCM at 0 °C. The mixture was warmed to RT 
and stirred for 2 h, at which time the reaction was diluted with DCM, extracted with ddH2O (3 x 25 mL) and brine (1 
x mL), dried over MgSO4, filtered, and concentrated to afford a white fluffy solid 4 (0.69 g, 75%). 1H NMR (500 
! S13 
MHz, CDCl3): δ 2.21 (s, 3H, CH3), 2.83 (s, 4H, CH2CH2-succinimide), and 2.86-2.92 (m, 4H, CH2CH2-levulinate). 
MS (ESI) calcd. for C9H11NO5+ [M + H+] 214.08, found 214.10.  
N-(2-(2-(6-Chlorohexyloxy)ethoxy)ethyl)-4-oxopentanamide (1). Trifluoroacetic acid (TFA) (0.14 mL, 1.8 mmol, 6 
eq) was added dropwise to a stirring solution of 3 (0.10 g, 0.31 mmol) in anhydrous DCM (5 mL). The mixture was 
stirred at RT for 4 h, then azeotroped with toluene, and concentrated to afford the free amine as a yellow oil, which 
was used without further purification. This intermediate (0.025 g, 0.074 mmol) was stirred with N,N-
diisopropylethylamine (DIPEA; 0.076 mL, 0.436 mmol, 6 eq) in anhydrous DCM (3 mL) for 20 min at RT, to which 
4 (0.016 g, 0.075 mmol, 1 eq) was added and stirred overnight. After 24 h, the reaction was diluted with DCM (20 
mL) and extracted with ddH2O (3 x 25 mL) and brine (1 x 25 mL), dried over MgSO4, filtered, and concentrated to 
afford a yellow oil. Purification by silica gel flash chromatography using 97:3 DCM/MeOH gave 1 as a colorless oil 
(0.016 g, 67%). 1H NMR (500 MHz, CDCl3): δ 1.33-1.41 (m, 2H, CH2), 1.42-1.49 (m, 2H, CH2), 1.56-1.65 (m, 2H, 
CH2), 1.73-1.81 (m, 2H, CH2), 2.18 (s, 3H, CH3), 2.43 (t, J = 6.6 Hz, 2H, CH2C(O)), 2.79 (t, J = 6.6 Hz, 2H, CH-
2C(O)), 3.41-3.49 (m, 4H, CH2Cl and CH2N), 3.51-3.56 (m, 4H, CH2O), 3.56-3.63 (m, 4H, CH2O), 6.15 (bs, 1H, 
NH). MS (ESI) calcd. for C15H28ClNO4+ [M + H+] 322.18, found 322.20. 
 
Synthesis of compounds for method validation. 
Fluorescein-chloroalkane linker conjugate (F-CL). To a solution of 1 (2.6 mg, 8.1 µmol) in 0.5 mL anhydrous 
MeOH was added 5-(((2-(carbohydrazino)methyl)thio)acetyl)aminofluorescein (F) in ddH2O (4.0 mg, 8.1 µmol, 1 
eq; C-356, Life Technologies). The mixture was stirred for 12 h at RT in the dark, concentrated, and purified by 
silica gel flash chromatography in the dark using a 97:3 DCM/MeOH mixture to afford the desired compound as an 
orange solid (4.8 mg, 75%). 1H NMR (500 MHz, D2O): δ 1.26-1.33 (m, 2H, CH2), 1.33-1.39 (m, 2H, CH2), 1.40 (s, 
3H, CH3), 1.44-1.52 (m, 2H, CH2), 1.63-1.70 (m, 2H, CH2), 3.32-3.55 (m, 20H, CH2), 6.42-6.48 (m, 2H, Ar-H) 
6.49-6.60 (m, 4H, Ar-H), 7.07 (dd, J = 8.3, 2.9 Hz, 1H, Ar-H), 7.73-7.81 (m, 1H, Ar-H), and 8.21-8.30 (m, 1H, Ar-
H). MS (ESI) calcd. for C39H43ClN4O10S-2Na+ [M-2 + Na+] 817.23, found 817.25. 
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Biotinylated heparan sulfate (B-HS). To a stirring solution of EZ-Link NHS-PEG4-biotin (0.10 g, 0.17 mmol; 21363, 
Thermo Scientific) in dry DCM (5 mL) was added a solution of ethylenediamine (0.022 mL, 0.33 mmol, 2 eq) and 
triethylamine (TEA; 0.15 mL, 1.1 mmol, 6 eq) in dry DCM (1 mL). The mixture immediately turned cloudy upon 
addition and was then stirred for 1.5 h at RT. The precipitate was filtered, and the reaction was concentrated to 
afford the conjugated amine as a white solid (0.068 g, 76%), which was used without further purification. De-6-O-
sulfated HS (7.0 mg, 0.58 µmol) was dissolved in ddH2O (1 mL), followed by the addition of cyanogen bromide in 
ddH2O (5.0 mg, 47 µmol, excess). The pH was adjusted to 11.0 using 0.2 M NaOH and stirred for 10 min. The 
mixture was then desalted on a PD-10 Sephadex column using 0.2 M sodium borate (pH 8.0). The HS fractions were 
pooled (3 mL) and immediately stirred with the biotin-conjugated amine (5.0 mg, 9.4 µmol, excess) overnight (12 h). 
The mixture was then flash frozen, lyophilized, redissolved in ddH2O (0.5 mL), and purified using a G-25 Sephadex 
column. The desired fractions were pooled, flash frozen, and lyophilized to afford B-HS as a white solid (99% 
recovery). 1H NMR (600 MHz, D2O): δ 3.29 (bs, 1H), 3.72-3.91 (m, 5H), 4.04-4.13 (m, 1H), 4.18-4.32 (m, 1H), 
4.33-4.44 (m, 1H), 4.84 (bs, 1H), 5.26 (bs, 1H, IdoA C-1), 5.42 (bs, 1H, GlcN C-1); substoichiometric: 1.30 (bs, 2H, 
CH2-biotinPEG4), 1.43 (bs, 2H, CH2-biotinPEG4), 1.50-1.52 (m, 2H, CH2-biotinPEG4), 2.05 (bs, 3H, NHAc), 2.29 (t, 
2H, CH2-biotinPEG4), 2.52-2.60 (m, 2H, CH2-biotinPEG4), 2.78-2.82 (m, 2H, C(O)CH2-biotinPEG4) 2.99-3.03 (m, 
1H, CH-biotinPEG4), 3.32-3.54 (m, 22H, CH2O- and CH2N-biotinPEG4). Biotin(PEG)4 incorporation was estimated 
to be 0.9 molecules per polysaccharide. 
Biotinylated heparan sulfate with chloroalkane linker (B-HS-CL). A solution of 1 (4.0 mg, 12 µmol, excess) and 
NaBH3CN (2.0 mg, 32 µmol, excess) in 1:1 MeOH:ddH2O (400 µL) was added to B-HS (2.0 mg, 0.17 µmol) in 
ddH2O (500 µL). MeOH (approximately 300 µL) was added until the reaction turned from cloudy to colorless, and 
the mixture was stirred for 12 h at RT, concentrated, and purified by gel filtration chromatography using G-25 
Sephadex resin. The pooled fractions containing the polysaccharide were lyophilized to yield a white powder (99% 
recovery). 1H NMR (600 MHz, D2O): δ 3.24 (bs, 1H), 3.62-3.89 (m, 5H), 4.04-4.14 (m, 1H), 4.17-4.32 (m, 1H), 
4.33-4.44 (m, 1H), 5.24-5.45 (m, 2H, IdoA C-1, GlcN C-1); substoichiometric: 1.07 (d, J = 6.3 Hz, 3H, CH3-CL), 
1.50-1.54 (m, 2H), 2.01 (s, 3H, NHAc), 2.18-2.23 (m, 6H), 2.34-2.45 (m, 2H), 2.75 (s, 2H), 2.99-3.10 (m, 2H). CL 
incorporation was estimated to be 1.8 CL molecules per polysaccharide.  
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Synthesis of compounds for biological assays. 
General procedure for chloroalkane heparin/heparan sulfate derivatives. In a typical procedure, 1 (4.0 mg, 12 µmol, 
excess) was dissolved in MeOH and ddH2O (1:1, 400 µL) with NaBH3CN (2.0 mg, 32 µmol, excess) and added to 
HS, de-HS, deO-HS, 6-deO-HS, or 2-deO-HS (2.0 mg, 0.17 µmol) in ddH2O (500 µL). MeOH (approximately 300 
µL) was added until the reaction turned from cloudy to colorless, and the mixture was stirred for 12 h at RT, 
concentrated, and purified by gel filtration chromatography using G-25 Sephadex resin. The pooled fractions 
containing the polysaccharides were lyophilized to yield white powders (99% recovery of polysaccharide in all 
cases). CL incorporation was estimated to be between 0.4 to 4 molecules per polysaccharide. 
HS-CL: 1H NMR (600 MHz, D2O): δ 3.29 (bs, 1H), 3.78-3.91 (m, 2H), 4.06 (bs, 1H), 4.12 (bs, 1H), 4.20-4.31 (m, 
2H), 4.33-4.44 (m, 2H), 4.91 (bs, 1H), 5.27-5.46 (m, 2H, IdoA C-1, GlcN C-1); substoichiometric: 1.19 (dd, J = 6.3, 
0.9 Hz, 3H, CH3-CL), 1.67-1.77 (m, 2H), 2.06 (bs, NHAc), 2.20-2.31 (m, 6H), 2.38-2.45 (m, 2H), 2.73 (s, 2H), 
2.77-2.86 (m, 2H). 
de-HS-CL: 1H NMR (600 MHz, D2O): δ 3.77-3.94 (m, 4H), 3.96-4.12 (m, 2H), 4.19-4.38 (m, 2H), 4.92 (bs, 1H), 
5.08-5.23 (m, 2H, IdoA C-1), 5.40 (bs, 1H, GlcN C-1); substoichiometric: 1.19 (d, J = 6.2 Hz, 3H, CH3-CL), 1.68-
1.77 (m, 2H), 2.02 (bs, 3H, NHAc), 2.41 (t, J = 6.8 Hz, 2H), 2.66 (s, 2H), 2.79 (t, J = 6.8 Hz, 2H). 
deO-HS-CL: 1H NMR (600 MHz, D2O): δ 3.26 (bs, 1H), 3.62-3.77 (m, 4H), 3.78-3.93 (m, 3H), 4.06 (bs, 1H), 4.12 
(bs, 1H), 4.95 (bs, 1H, IdoA C-1), 5.38 (bs, 1H, GlcN C-1); substoichiometric: 1.19 (d, J = 6.3 Hz, 3H, CH3-CL), 
1.70-1.75 (m, 2H), 2.04 (bs, 3H, NHAc), 2.21-2.26 (m, 6H), 2.40-2.43 (m, 2H), 2.66 (s, 2H), 2.78 (t, J = 6.9 Hz, 
2H). 
6-deO-HS-CL: 1H NMR (600 MHz, D2O): δ 3.26 (bs, 1H), 3.64-3.95 (m, 5H), 4.05 (bs, 1H), 4.26 (bs, 1H), 4.36 (bs, 
1H), 4.93 (bs, 1H), 5.28-5.41 (m, 2H, IdoA C-1, GlcN C-1); substoichiometric: 1.19 (dd, J = 6.3, 1.7 Hz, 3H, CH3-
CL), 1.69-1.76 (m, 2H), 2.06 (bs, 3H, NHAc), 2.18-2.30 (m, 6H), 2.41 (td, J = 6.9, 1.7 Hz, 3H), 2.66 (d, J = 1.7 Hz, 
2H), 2.79 (td, J = 6.9, 1.5 Hz, 2H). 
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2-deO-HS-CL: 1H NMR (600 MHz, D2O): δ 3.26 (bs, 1H), 3.60-3.93 (m, 5H), 3.94-4.29 (m, 3H), 4.35 (bs, 1H), 
5.30-5.45 (m, 2H, GlcN C-1, IdoA C-1); substoichiometric: 1.19 (d, J = 6.3 Hz, 3H, CH3-CL), 1.69-1.77 (m, 2H), 
2.05 (bs, 3H, NHAc), 2.21-2.34 (m, 6H), 2.44 (t, J = 6.8 Hz, 2H), 2.72-2.83 (m, 4H). 
 
General biological procedures. 
Transmembrane HaloTag protein DNA construct. The sequence encoding the HaloTag protein (HTP) was PCR 
amplified from the pFC14K HT7 CMV Flexi Vector (Promega) using the primers 5’-TT ATC CGC GGT GGA 
TCC GAA ATC GGT ACT GGC TTT-3’ (upstream) and 5’-A CTA GTC GAC ACC GGA AAT CTC CAG AGT 
AGA CAG-3’ (downstream) to introduce a 5’ SacII restriction site and a 3’ SalI restriction site. The PCR product 
was digested with SalI and SacII according to standard procedures and gel purified. The pDisplay vector (pD; Life 
Technologies) was linearized with SalI and SacII according to standard procedures and purified using a QIAquick 
PCR purification kit (Qiagen, Valencia, CA). The insert was ligated into the linearized vector using T4 DNA ligase. 
The HTP gene was inserted between the sequence encoding the N-terminal murine Ig κ-chain leader and the C-
terminal PDGFR transmembrane domain to generate the final HTP construct. The plasmid was confirmed by Sanger 
sequencing (Laragen Inc.). 
Cell culture. All cell cultures were maintained at 37 °C and 5% CO2 unless otherwise indicated. CHO cells were 
cultured on tissue culture plates in F12 medium supplemented with 10% FBS and 1% P/S and were passaged after 
reaching ~80% confluency. mESCs were cultured strictly according to ATCC protocols to maintain a homogeneous 
population of pluripotent cells. Confluent MEFs were treated with mitomycin C (10 µg/mL in DMEM with 10 % 
FBS and 1% P/S) for 3 h at 37 °C to provide a feeder cell layer for mESCs. mESCs were cultured directly on the 
MEF feeder layer in DMEM (ATCC) with 10% non-heat-inactivated FBS and 0.1 mM β-mercaptoethanol (defined 
henceforth as complete DMEM). To passage or isolate mESCs for transfection, collagenase IV (10 µg/mL) in DPBS 
(with CaCl2 and MgCl2) was equilibrated to 37 °C and 5% CO2 and added to mESCs (3 mL) and allowed to detach 
the cells for 3-5 min at 37 °C. The cells were gently agitated to remove the large colonies, leaving the majority of 
remaining MEFs attached to the plate. The released mESCs were then added to 6 mL of pre-warmed complete 
DMEM and centrifuged (1,200 rpm for 2.5 min). The collagenase IV-containing medium was aspirated, and the 
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cells were resuspended in 10 mL of fresh pre-warmed complete DMEM. At this time, the cells were either 
transferred to new tissue culture plates on top of a confluent layer of mitomycin C-treated MEFs for further culture 
or to plates pre-coated with 0.2% gelatin for transfection. mESCs were passaged every 3 to 5 days, depending on 
their colony sizes and proximity to one another, and the medium was replaced every 2 days. 
HTP transfections. CHO cells were plated and transfected with the HTP plasmid using Lipofectamine LTX (Life 
Technologies) according to the manufacturer’s protocol. For transfecting mESCs, the protocol for XfectTM mESC 
Transfection Reagent was followed. Briefly, mESCs were plated on 0.2% gelatin-coated 6-well plates at 1 x 106 
cells/well in complete DMEM. After 5 h, the HTP plasmid-lipid transfection complexes were generated and added 
according to the manufacturer’s instructions. The mESCs were then incubated for 3 h with the transfection 
complexes at 37 °C and 5% CO2, and the medium was replaced with 2 mL of pre-warmed complete DMEM. 
Generation of an HTP-expressing stable cell line. CHO cells lacking galactosyltransferase I (and therefore lacking 
glycosaminoglycans) that had been transfected with HTP were selected using complete F12 medium supplemented 
with 700 µL of G418 solution (0.8 mg/mL). The medium was replaced every 2 d for 3 weeks. After 3 weeks, the 
cells were incubated with fresh F12 medium containing 5 µM F-CL for 1 h (37 °C, 5% CO2) and then sorted via 
fluorescence-activated cell-sorting (FACS) using a FACSAria Flow Cytometer Cell Sorter (BD Biosciences) with an 
excitation wavelength of 488 nm. 
HTP labeling for fluorescent imaging analyses. CHO cells were plated and cultured on poly-ornithine-coated (10 
µg/mL) glass coverslips in complete F12 medium (10% FBS, 1% P/S) at 37 °C and 5% CO2. For labeling, the 
medium was replaced with fresh F12 medium that contained 5 µM F or F-CL for 1 h (37 °C, 5% CO2). The cells 
were then washed with PBS (2 x 1 mL), fixed with 4% paraformaldehyde in PBS (15 min at RT), rinsed with PBS 
(2 x 1 mL), permeabilized with a solution containing 1% BSA and 0.1% Triton X-100 (20 min at RT), incubated 
with a monoclonal mouse anti-Myc antibody (1:1000; 12 h at 4 °C), washed with PBS (2 x 5 min), incubated with a 
goat anti-mouse AF568 secondary antibody (1:1000; 1 h at RT), and washed with PBS (2 x 5 min). The coverslips 
were mounted with VECTASHIELD mounting medium containing DAPI (Vector Laboratories Inc., Burlingame, 
CA) and imaged using a Zeiss LSM 700 inverted confocal microscope.  
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HTP labeling for Western blot analyses. CHO cells stably expressing HTP were cultured on 10-cm plates in 
complete F12 medium until approximately 85% confluent. The medium was then replaced with fresh F12 medium 
(4 mL) that contained 5 µg/mL B-HS, or B-HS-CL, and the cells were incubated for 6 h at 37 °C. After labeling, the 
medium was removed, and the cells were scraped and collected in cold PBS (1 mL), centrifuged (3,000 rpm for 2.5 
min at 4 °C), and homogenized in 150 µL of lysis buffer (50 mM Tris/HCl pH 7.4, 250 mM mannitol, 50 mM NaF, 
1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM Na2VO4, 1% Triton X-100, and 1x cOmplete protease inhibitor 
cocktail (Roche, Pleasanton, CA) via 10 passages through a 26g x 3/8” needle on ice. The lysates were then clarified 
by centrifugation (15,000 rpm for 15 min at 4 °C) and transferred to clean microcentrifuge tubes, after which the 
total protein concentration was determined for each sample using the Bradford assay (Bio-Rad Laboratories). 
Samples were boiled for 5 min with SDS-PAGE loading buffer and resolved by SDS-PAGE on 4-12% Bis-Tris gels 
(Life Technologies). Proteins were transferred to PVDF membranes and blocked with blocking buffer (5% milk in a 
solution of 50 mM Tris pH 7.6, 150 mM NaCl, and 0.5% Tween-20 (TBST)) for 1 h at RT. Blots were incubated 
with IRDye800 streptavidin (1:1000; LI-COR Biosciences, Lincoln, NE) and an anti-HA rabbit monoclonal 
antibody (1:1000) overnight at 4 °C in blocking buffer, rinsed twice with TBST, and incubated again with an 
AF680-conjugated goat anti-rabbit IgG antibody (1:10000) for 1 h at RT. Membranes washed three times with 
TBST for 5 min at RT and were then imaged and quantified using an Odyssey scanner (LI-COR Biosciences).  
HTP-conjugate lifetime assay. CHO cells were plated onto 15-mm coverslips, cultured, and labeled with 5 µM F or 
F-CL in F12 medium for 1 h (37 °C, 5% CO2). Cells were rinsed once with prewarmed PBS and subsequently 
cultured with fresh F12 medium (37 °C, 5% CO2). At each time point (between 0.5 and 8 d), the coverslips were 
removed from culture, submerged in PBS for 2 min, fixed with 4% paraformaldehyde in PBS for 15 min, and then 
washed in PBS for 5 min. The coverslips were blotted dry, mounted onto glass microscope slides using 
VECTASHIELD mounting medium containing DAPI, and imaged using a Zeiss LSM 700 inverted confocal 
microscope. 
Microarray analyses. Glycosaminoglycan microarrays were generated as previously described.4 Slides were blocked 
with 10% FBS in PBS for 1 h at RT. Stock solutions of FGF2, FGF8b, FGFR1-Fc (2 µM), and FGFR3c-Fc were 
prepared in sterile 1x PBS containing 1% BSA. Blocked slides were washed once with PBS and slowly rocked with 
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150 µL of 1% BSA/PBS containing 1 µM receptor with or without 1 µM ligand (i.e., 1 µM FGFR1-Fc ± 1 µM 
FGF2; 1 µM FGFR3-Fc ± 1 µM FGF8b) for 2 h at RT. Slides were washed three times with PBS and incubated with 
an AF647-conjugated goat anti-human Fc antibody (1:5000) in 1% BSA/PBS for 1 h at RT in the dark with gentle 
rocking. Slides were then washed three times with PBS and twice with ddH2O and blown dry under a stream of 
filtered air. Arrays were scanned using a G2565BA DNA Microarray Scanner (Agilent), and fluorescence was 
quantified using GenePix 5.0 software (Molecular Devices) with normalization against local background. The data 
represent the average of 10 spots per concentration of polysaccharide. 
ERK activation assays. Pluripotent mESCs were transfected with the HTP plasmid as described above. After 48 h, 
the cells were detached with collagenase IV (10 µg/mL, 3 mL) in DPBS, pelleted, and resuspended in 2 mL of 
complete DMEM containing 1 U/mL heparinase II (HepII, Sigma-Aldrich) for 2 h at 37 °C with gentle mixing every 
15 min. HepII was quenched with 6 mL of complete DMEM, and the cells were pelleted and resuspended in 
complete DMEM. mESCs were then plated on six-well plates coated with 0.2% gelatin and incubated with HS-CL, 
de-HS-CL, deO-HS-CL, 6-deO-HS-CL, or 2-deO-HS-CL (5 µg/mL) overnight. Cells were serum-starved the 
following day with DMEM containing 0.5% FBS for 8 h and then stimulated for 15 m with DMEM containing 0.5% 
FBS and 10 ng/mL of FGF2. Cells were then quickly washed with 1 mL of ice-cold PBS, scraped, and pelleted. The 
pellet was lysed and homogenized as described above. Samples were boiled for 5 min with SDS-PAGE loading 
buffer, resolved by SDS-PAGE on 4-12% Bis-Tris gels, transferred to PVDF membrane, and blocked for 1 h at RT 
with Odyssey Blocking Buffer (LI-COR Biosciences). Membranes were immunoblotted with a rabbit anti-phospho-
ERK monoclonal antibody (1:2000) overnight at 4 °C and then a mouse anti-ERK monoclonal antibody (1:2000) for 
1 h at RT. Blots were then incubated with an AF680-conjugated goat anti-mouse IgG antibody (1:10000) and 
IRDye800-conjugated goat anti-rabbit IgG antibody (1:10000) for 1 h at RT. Membranes were washed three times 
with TBST for 5 min and then imaged and quantified using an Odyssey scanner (LI-COR Biosciences). Ratios of 
phospho-ERK to total ERK were calculated for each condition and normalized to an untreated control. Statistical 
analysis was performed using a one-way ANOVA with post-hoc analysis by Dunnett’s test against the untreated 
control. Data represent the mean ± S.E.M. for three independent experiments (n = 3). 
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Neuronal differentiation assays. Pluripotent mESCs were transfected with the HTP plasmid and HepII treated as 
described above. The reaction was quenched with 6 mL of complete DMEM, pelleted, and resuspended in 1 mL of 
neural induction medium (1 part DMEM:F12 (1:1) 1% N-2 supplement, 1% P/S and 1 part Neurobasal, 1% 
GlutaMAX, 1% B-27, 1% P/S). HepII-treated cells were then added to 0.2% gelatin-coated plates in 2 mL of neural 
induction medium containing FGF2 (10 ng/mL) and HS-CL derivatives (untreated, HS-CL, or de-HS-CL; 5 µg/mL). 
The medium was replaced after 48 h with fresh neural induction medium containing FGF8b (10 ng/mL). At 3, 6, and 
9 days after HepII treatment, the cells were subjected to RNA isolation for qRT-PCR and immunocytochemistry 
analyses. 
Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). mESCs were cultured and 
subjected to neuronal differentiation as described above. At different time points (Day 3, 6, and 9), RNA was 
extracted from untreated cells and cells treated with HS-CL or de-HS-CL using the RNeasy Mini Kit (Qiagen) per 
the manufacturer’s instructions. RNA concentrations were obtained with a NanoDrop 2000 UV-Vis 
spectrophotometer (Thermo Scientific), and then the RNA samples were converted to cDNA using the iScript 
Advanced cDNA Synthesis Kit (Bio-Rad). qRT-PCR was performed using an Applied Biosciences 7300 Real-Time 
PCR System with primers for GAPDH, SDHA, NANOG, SOX1, and TUJ1 (Table S1). The following conditions 
were used for each 20-µL qRT-PCR reaction: 5 µL of cDNA (10 ng/µL), 1 µL of primer mixture (10 µM forward 
and 10 µM reverse), 10 µL of 2x SYBR master mix, and 4 µL of ddH2O. The cycle threshold (Ct) values for 
NANOG, SOX1, and TUJ1 were first normalized against the geometric mean of GAPDH and SDHA at each 
condition and time point. Each data point was then normalized to the untreated value at day 3 to report relative 
changes. Statistical analysis was performed for each gene at each time point using a one-way ANOVA with post-hoc 
analysis by Dunnett’s test against the untreated control. Data represent the mean ± S.E.M. from two samples run in 
triplicate (n = 2).    
Immunocytochemistry. Untreated mESCs and mESCs treated with HS-CL or de-HS-CL were subjected to neuronal 
differentiation as described above. At 3, 6, and 9 days after HepII treatment, mESCs were fixed with 4% 
paraformaldehyde in PBS (15 min), rinsed with PBS (2 x 1 mL), permeabilized with a solution containing 1% BSA 
and 0.1% Triton X-100 (20 min), and incubated with a rabbit anti-NANOG monoclonal antibody (1:1000), a goat 
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anti-SOX1 polyclonal antibody (1:250), or a rabbit anti-TUJ1 monoclonal antibody (1:1000) for 3 h at RT. Cells 
were washed with PBS (2 x 1 mL) and then incubated with an AF488-conjugated goat anti-rabbit antibody (1:5000), 
AF568-conjugated donkey anti-goat antibody (1:5000), or AF568-conjugated goat anti-mouse antibody (1:5000), 
respectively, for 1 h at RT. Cells were imaged using a Zeiss LSM 700 inverted confocal microscope.  
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1H NMR spectra of representative compounds. 
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6-deO-HS-CL 
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